Patents by Inventor Kyle J. Eastman

Kyle J. Eastman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic compounds for treatment of medical disorders
    Patent number: 11053253
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 6, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Dawei Chen, Venkat Rao Gadhachanda, Joel Charles Barrish, Atul Agarwal, Kyle J. Eastman
  • Phosphatase Binding Compounds and Methods of Using Same
    Publication number: 20200268897
    Abstract: The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.
    Type: Application
    Filed: January 8, 2020
    Publication date: August 27, 2020
    Inventors: Craig Crews, Samuel W. Gerritz, Kyle J. Eastman, Katherine J. Kayser-Bricker, Jinshan M. Chen, David E. Puleo
  • Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders
    Publication number: 20200071301
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20200055839
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: February 20, 2020
    Inventors: Makonen BELEMA, Michael S. BOWSHER, Jeffrey A. DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20200016136
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: January 16, 2020
    Inventors: Michael S. BOWSHER, Jeffrey DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20200002347
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 2, 2020
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Dawei Chen, Venkat Rao Gadhachanda, Joel Charles Barrish, Atul Agarwal, Kyle J. Eastman
  • PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20190382376
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: August 29, 2019
    Publication date: December 19, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
    Patent number: 10351546
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 16, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, B. Narasimhulu Naidu, Kyle E. Parcella, Manoj Patel, Prasanna Sivaprakasam, Yong Tu
  • 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20190092754
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 28, 2019
    Inventors: Kyle J. EASTMAN, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C
    Patent number: 10214534
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: February 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Kyle E. Parcella, Kyle J. Eastman, John F. Kadow
  • Substituted pyridines as inhibitors of human immunodeficiency virus replication
    Patent number: 10189816
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 29, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
    Patent number: 10065953
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: September 4, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Timothy P. Connolly, Kyle J. Eastman, B. Narasimhulu Naidu, Kevin Peese
  • 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180230129
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Kyle J. EASTMAN, John F. KADOW, Kyle E. PARCELLA, B. Narasimhulu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180230124
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Kyle J. EASTMAN, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Manoj PATEL, Prasanna SIVAPRAKASAM, Yong TU
  • IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180222901
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 9, 2018
    Inventors: Timothy P. CONNOLLY, Kyle J. EASTMAN, B. Narasimhulu NAIDU, Kevin PEESE
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180147196
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: July 7, 2016
    Publication date: May 31, 2018
    Inventors: Kyle J. EASTMAN, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Manoj PATEL, Yong TU
  • Furopyridine compounds for the treatment of hepatitis C
    Patent number: 9957278
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 1, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, John F. Kadow
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9938271
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 10, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, B. Narasimhulu Naidu, Kyle E. Parcella, Kevin Peese
  • FUROPYRIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170247385
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 31, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, John F. Kadow
  • Fused furans for the treatment of hepatitis C
    Patent number: 9738653
    Abstract: The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Kyle J. Eastman, Kyle E. Parcella